Cedars-Sinai Medical Center, Los Angeles, has partnered with GenomeDx Biosciences, San Diego, on the Decipher genomics resource information database (Decipher GRID), a clinical genomics data-sharing program that unites physicians with GenomeDx’s full genome profiling platform.

By joining the Decipher GRID, the largest accessible genomic expression database for urologic cancers, clinicians at Cedars-Sinai can utilize real-time genomic data for the patients they treat and ultimately make more personalized treatment decisions. Over time, data collected will be used to study even larger populations of patients to identify biomarkers that may be predictive of treatment response.

Through the program, Cedars-Sinai will also use GenomeDx’s commercially available Decipher prostate cancer classifier to aid with treatment decisions following prostate cancer surgery. GenomeDx is conducting whole genome profiling for patients included in the program and matching those data to prospectively collected clinical outcomes for patients treated at major cancer centers.

Doug Dolginow

Doug Dolginow, MD, GenomeDx.

“GenomeDx has built a tremendous genomic repository in GRID, and through partnerships with groups like Cedars-Sinai we can marry the power of genomic information with prospective clinical outcomes for patients,” says Doug Dolginow, MD, chief executive of GenomeDx. “The only way to truly accelerate our understanding of the molecular implications of this disease is to make available and evaluate large datasets. The collaborative nature of GRID allows us to do just that.”

Hyung Kim, MD, Cedars-Sinai.

Hyung Kim, MD, Cedars-Sinai.

Hyung Kim, MD, director of academic urology and associate director of surgical research at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, adds, “Decipher GRID will provide us with research-based genomic information that will allow us to make discoveries to better serve our patients.”

The program around Decipher GRID is initially for men with prostate cancer and is expected to expand into other urologic cancers.

For more information, visit GenomeDx Biosciences.